Cellectar Biosciences, Inc. 8-K

What Happened
Cellectar Biosciences, Inc. (CLRB) announced in a Form 8-K filed July 10, 2026 (Item 5.07) that its stockholders approved an amendment to the company’s 2021 Stock Incentive Plan to increase the number of shares reserved for issuance under the Plan by 2,000,000 shares. The amended plan is filed as Exhibit 10.1 to the Current Report.

Key Details

• Stockholder vote reported on Form 8-K filed July 10, 2026 (Item 5.07).
• The 2021 Stock Incentive Plan was amended to add 2,000,000 shares reserved for issuance.
• The amended plan is included as Exhibit 10.1 to the filing; the filing also contains the Inline XBRL cover page (Exhibit 101).

Why It Matters
The amendment increases the number of shares available for equity grants under Cellectar’s incentive plan, enabling the company to grant additional stock-based compensation to employees, directors or consultants. That flexibility can support hiring and retention programs; if and when awards are granted and shares are issued, the total shares outstanding would rise, which can affect per-share measures. Investors should note the change as a potential source of future share issuance and monitor subsequent disclosures about any grants under the amended plan.